Adaptive Biotechnologies (FRA:1HM) Debt-to-Revenue : 0.58 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Adaptive Biotechnologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €8.8 Mil. Adaptive Biotechnologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €79.9 Mil. Adaptive Biotechnologies's annualized Revenue for the quarter that ended in Mar. 2024 was €154.1 Mil. Adaptive Biotechnologies's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.58.

Adaptive Biotechnologies Debt-to-Revenue Historical Data

The historical data trend for Adaptive Biotechnologies's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Debt-to-Revenue Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.43

1.10

0.72

0.58

Adaptive Biotechnologies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Revenue	Get a 7-Day Free Trial															0.70	0.53	0.67	0.54	0.58

Competitive Comparison of Adaptive Biotechnologies's Debt-to-Revenue

For the Biotechnology subindustry, Adaptive Biotechnologies's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Debt-to-Revenue falls into.

Adaptive Biotechnologies Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Adaptive Biotechnologies's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(8.605	+	81.969)	/	156.143
	=	0.58

Adaptive Biotechnologies's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(8.826	+	79.948)	/	154.092
	=	0.58

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.

Adaptive Biotechnologies Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies (FRA:1HM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

ADPT:USA 1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines